51 related articles for article (PubMed ID: 31077657)
1. Neoadjuvant Therapy Vs Upfront Surgery for Clinical T2N0 Esophageal Cancer: A Systematic Review.
Kidane B; Korst RJ; Weksler B; Farrell A; Darling GE; Martin LW; Reddy R; Sarkaria IS
Ann Thorac Surg; 2019 Sep; 108(3):935-944. PubMed ID: 31077657
[TBL] [Abstract][Full Text] [Related]
2. Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis.
Lee Y; Samarasinghe Y; Lee MH; Thiru L; Shargall Y; Finley C; Hanna W; Levine O; Juergens R; Agzarian J
Ann Surg; 2022 Jan; 275(1):91-98. PubMed ID: 34596073
[TBL] [Abstract][Full Text] [Related]
3. Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis.
Aliseda D; Arredondo J; Sánchez-Justicia C; Alvarellos A; Rodríguez J; Matos I; Rotellar F; Baixauli J; Pastor C
Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38381934
[TBL] [Abstract][Full Text] [Related]
4. Clinical T2 N0 M0 Esophageal Cancer: Identifying Predictive Factors of Upstaging.
Tasnim S; Raja S; Blackstone EH; Toth AJ; Barron JO; Raymond DP; Bribriesco AC; Schraufnagel DP; Murthy SC; Sudarshan M
Ann Thorac Surg; 2024 Jun; 117(6):1121-1127. PubMed ID: 38307482
[TBL] [Abstract][Full Text] [Related]
5. Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy.
Engelman E; Maeyens C
J Gastrointest Surg; 2010 May; 14(5):788-804. PubMed ID: 20229072
[TBL] [Abstract][Full Text] [Related]
6. Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis.
Su F; Yang X; Yin J; Shen Y; Tan L
Ann Surg Oncol; 2023 Nov; 30(12):7461-7471. PubMed ID: 37400616
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant therapy or upfront surgery in advanced endometrial cancer: a systematic review protocol.
McCarthy A; Balfour K; El Sayed I; Edmondson R; Wan YL
BMJ Open; 2021 Nov; 11(11):e054004. PubMed ID: 34764178
[TBL] [Abstract][Full Text] [Related]
8. ASO Author Reflections: The Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis.
Su F; Yang X; Yin J; Shen Y; Tan L
Ann Surg Oncol; 2023 Nov; 30(12):7507-7508. PubMed ID: 37349616
[No Abstract] [Full Text] [Related]
9. Responses to commentary on 'Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis' ( Int J Surg 2022 ;106:106929).
Wang Z; Wang Y; Feng Y; Yan X
Int J Surg; 2023 Jun; 109(6):1825-1834. PubMed ID: 37132181
[No Abstract] [Full Text] [Related]
10. Editorial: Frontiers' research topic "advances in esophageal cancer surgery with neoadjuvant therapies".
Shang QX; Hong ZN; Kang MQ; Chen LQ
Front Surg; 2023; 10():1242293. PubMed ID: 38033532
[No Abstract] [Full Text] [Related]
11. Erratum to: Apoptotic and proliferative indexes in esophageal cancer: Predictors of response to neoadjuvant therapy apoptosis and proliferation in esophageal cancer.
Beardsmore DM; Verbeke CS; Davies CL; Guillou PJ; Clark GWB
J Gastrointest Surg; 2003 Aug; 7(4):583. PubMed ID: 29340976
[No Abstract] [Full Text] [Related]
12. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.
Jing SW; Qin JJ; Liu Q; Zhai C; Wu YJ; Cheng YJ; Czito BG; Wang J
Future Oncol; 2019 Jul; 15(20):2413-2422. PubMed ID: 31269806
[No Abstract] [Full Text] [Related]
13. Recent progress in multidisciplinary treatment for patients with esophageal cancer.
Watanabe M; Otake R; Kozuki R; Toihata T; Takahashi K; Okamura A; Imamura Y
Surg Today; 2020 Jan; 50(1):12-20. PubMed ID: 31535225
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy or Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Sun HB; Yan S; Liu XB; Xing WQ; Chen PN; Liu SL; Li P; Ma YX; Lerut T; Daoud A; Jiang D
Ann Surg Oncol; 2024 Apr; 31(4):2443-2450. PubMed ID: 37962741
[TBL] [Abstract][Full Text] [Related]
15. Prognostic nomogram and risk factors for predicting survival in patients with pT2N0M0 esophageal squamous carcinoma.
Kang M; Wang Y; Yang M; Wang X; Zhu L; Zhang M
Sci Rep; 2023 Mar; 13(1):4931. PubMed ID: 36967413
[TBL] [Abstract][Full Text] [Related]
16. Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment?
Perez Holguin RA; Olecki EJ; Stahl KA; Wong WG; Vining CC; Dixon MEB; Peng JS
J Gastrointest Surg; 2022 Oct; 26(10):2050-2060. PubMed ID: 36042124
[TBL] [Abstract][Full Text] [Related]
17. Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma.
Stüben BO; Stuhlfelder J; Kemper M; Tachezy M; Ghadban T; Izbicki JR; Bokemeyer C; Sinn M; Karstens KF; Reeh M
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205833
[TBL] [Abstract][Full Text] [Related]
18. Impact of chemotherapy and radiotherapy on the survival of elderly esophageal cancer patients undergoing surgery: a SEER database analysis.
Li X; Zhang J; Ye C; Zhu J; Guo K; Guo Y
BMC Gastroenterol; 2021 Nov; 21(1):430. PubMed ID: 34794384
[TBL] [Abstract][Full Text] [Related]
19. LncRNA-NBAT-1 modulates esophageal cancer proliferation via PKM2.
Zhao B; Cao P; Hu S; Li F; Kong K; Zu Y
Am J Transl Res; 2019; 11(9):5978-5987. PubMed ID: 31632565
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
